  G protein coupled receptors (GPCRs) produce pleiotropic effects by their
capacity to engage numerous signaling pathways once activated. Functional
selectivity (also called biased signaling), where specific compounds can bring
GPCRs to adopt conformations that enable selective receptor coupling to
distinct signaling pathways, continues to be significantly investigated.
However, an important but often overlooked aspect of functional selectivity is
the capability of ligands such as angiotensin II (AngII) to adopt specific
conformations that may preferentially bind to selective GPCRs structures.
Understanding both receptor and ligand conformation is of the utmost importance
for the design of new drugs targeting GPCRs. In this study, we examined the
properties of AngII cyclic analogs to impart biased agonism on the angiotensin
type 1 receptor (AT1R). Positions 3 and 5 of AngII were substituted for
cysteine and homocysteine residues ([Sar1Hcy3,5]AngII, [Sar1Cys3Hcy5]AngII and
[Sar1Cys3,5]AngII) and the resulting analogs were evaluated for their capacity
to activate the Gq/11, G12, Gi2, Gi3, Gz, ERK and \b{eta}-arrestin (\b{eta}arr)
signaling pathways via AT1R. Interestingly, [Sar1Hcy3,5]AngII exhibited potency
and full efficacy on all pathways tested with the exception of the Gq pathway.
Molecular dynamic simulations showed that the energy barrier associated with
the insertion of residue Phe8 of AngII within the hydrophobic core of AT1R,
associated with Gq/11 activation, is increased with [Sar1Hcy3,5]AngII. These
results suggest that constraining the movements of molecular determinants
within a given ligand by introducing cyclic structures may lead to the
generation of novel ligands providing more efficient biased agonism.
